TearSolutions has announced that its investigational peptide therapy, Lacripep, is moving into a Phase 2 clinical trial for the treatment of neurotrophic keratitis, a rare and potentially vision-threatening condition caused by reduced corneal sensation. The advancement follows the U.S. Food and Drug Administration granting the therapy two separate special designations, underscoring regulatory recognition of its potential to address a significant unmet medical need.
Lacripep is derived from lacritin, a naturally occurring protein found in human tears that plays a role in maintaining a healthy ocular surface. By harnessing a peptide fragment of this natural protein, TearSolutions aims to restore protective tear film function and support corneal healing in patients whose eyes have lost normal sensory feedback due to nerve damage. Neurotrophic keratitis can lead to persistent epithelial defects and, if untreated, more serious complications, making new therapeutic options especially valuable for patients and eye care specialists alike.
The dual FDA designations granted to Lacripep are typically awarded to therapies that show promise for treating rare or serious conditions with limited existing treatment options. These designations can provide benefits such as closer collaboration with regulators, potential eligibility for expedited review pathways, and additional development incentives — all of which can help accelerate the path toward patients who need new options.
Moving into Phase 2 testing represents an important step in validating earlier research suggesting that Lacripep may help promote corneal surface repair using a naturally inspired mechanism rather than more invasive interventions. If the upcoming trial continues to demonstrate encouraging safety and efficacy signals, it could represent a meaningful advance for patients living with neurotrophic keratitis, a condition that currently has few targeted treatment options.
The progress of Lacripep also reflects the broader promise of peptide-based therapeutics in ophthalmology, where naturally derived molecules are increasingly being explored for their ability to support tissue repair with a favorable safety profile. As TearSolutions moves forward with this next phase of testing, the eye care community will be watching closely for results that could expand treatment possibilities for this challenging condition.
This article is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply